

StemCells

Pipeline update

Critical juncture in spinal cord injury

StemCells has reached a critical juncture in its development program with a highly encouraging interim analysis of its Phase II PATHWAY study pointing to promising efficacy in cohort 1 of its human central nervous system stem cells (HuCNS-SC) in lead indication spinal cord injury (SCI). Given limited financial resources, StemCells is realigning operations to focus efforts on the internal funding for key pivotal Phase III SCI trials. New group leadership by way of a recently announced change in CEO comes on the heels of the current company reorganization.

Year end	Revenue (\$m)	PBT* (\$m)	EPS* (\$)	DPS (\$)	P/E (x)	Yield (%)
12/13	1.2	(29.7)	(0.68)	0.0	N/A	N/A
12/14	1.0	(32.2)	(0.56)	0.0	N/A	N/A
12/15e	0.1	(37.6)	(0.39)	0.0	N/A	N/A
12/16e	0.2	(26.7)	(0.25)	0.0	N/A	N/A

Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.

Evidence of efficacy validates HuSNC-SC platform

Early proof-of-concept data in cohort 1 of the PATHWAY study in SCI announced in November 2015 provided StemCells with the first meaningful signs of efficacy of its stem cells technology, and also provided hope for patients with no alternative treatment options. Patients with no motor function from the point of injury downward showed signs of improvement at six months in muscle function and dexterity on traditional neurological tests as well as patient self-assessed quality-of-life scales. We expect 12-month data from cohort 1 in the first half of 2016 and an interim analysis on the larger cohort 2 by the end of 2016.

Restructuring implemented as resources are shuffled

At the end of last year StemCells announced a realigning of the company to ensure sufficient capital to move its promising Phase II program in SCI forward through Phase II and into pivotal Phase III trials. Cost-cutting entails a 25% reduction in staff and the temporary halting of the Phase II program in geographic atrophy of age-related macular degeneration (GA-AMD) as alternative financing, potentially through a partner, is sought for this indication. Management aims to save ~\$20m over the next two years.

Valuation: Moves to \$84m from \$198m

Our DCF-based, sum-of-the-parts valuation moves to \$84m (\$0.77per share) from \$198m (\$1.82 per share) as we push back our forecasts in AMD by two years and decrease the probability of success on increased uncertainty related to the program. The decrease is partially offset by an increase in value in SCI on the positive Phase II interim data. We expect StemCells will need financing in the first half of 2016 based on our estimate of cash on hand of \$11.9m at the close of 2015 and our forecasts therefore include an illustrative \$30m in bank debt in 2016.

Pharma & biotech

5 February 2016

Price US\$0.34
Market cap US\$37m

Net cash (\$m) at September 2015 excluding forgivable CIRM loan	18.7
Shares in issue	108.8m
Free float	93%
Code	STEM
Primary exchange	NASDAQ
Secondary exchange	N/A

Share price performance



%	1m	3m	12m
Abs	(17.8)	(20.1)	(69.1)
Rel (local)	(13.6)	(12.3)	(67.0)
52-week high/low	US\$1.4	US\$0.3	

Business description

StemCells is a US biotech company developing stem cell-based therapeutics. The lead clinical program, based on HuCNS-SC (human neural stem cells) for spinal cord injury (SCI) is in Phase II trial while dry age-related macular degeneration (AMD) is being temporarily halted.

Next events

Interim 12-month data PATHWAY study (cohort 1) cervical SCI	Q216
Interim analysis (cohort 2) PATHWAY study cervical SCI	H216
Final PATHWAY study data cervical SCI	2017
Full-year results	Mar 2016

Analysts

Katherine Genis	+1 646 653 7026
Christian Glennie	+44 (0)20 3077 5727

healthcare@edisongroup.com

[Edison profile page](#)

StemCells is a research client of Edison Investment Research Limited

StemCells focusing resources on SCI

At the end of December 2015 StemCells announced a strategic realignment and restructuring program to channel its finances on its HuCNS-SC as a treatment in its lead indication, chronic SCI, thereby temporarily suspending its ongoing development for HuCNS-SC in geographic atrophy of GA-AMD. The news followed the highly promising interim Phase II results in SCI announced last November. While management has temporarily halted the Phase II trial in GA-AMD in conjunction with the prioritization of its clinical programs, the company continues to seek out a strategic partnership in retinal disorders and have in fact reported some recent third-party interest in the program.

The restructuring of the company entails cost-cutting to save an estimated \$20m over the next two years, which includes, among other measures, a reduction of its workforce by ~25% (targeted for the end of January 2016). These savings will enable the focus of its resources on the development of its program in SCI, which is to include the completion of the Phase II PATHWAY study and start of a pivotal Phase III trial for which the company has begun the scaling up of manufacturing.

Phase II in SCI shows promising evidence of restored function

StemCells' PATHWAY study, consisting of three cohorts, will enrol a total of 52 patients and primarily focuses on change in upper extremity strength as measured in the hands, arms and shoulders for up to 12 months post-transplant in motor complete injury.

In November 2015, StemCells reported highly encouraging preliminary data in cohort 1 of PATHWAY pointing toward the potential for a dramatic improvement in quality of life for patients with complete motor control loss due to trauma. In the six-patient trial noteworthy improvements were seen in muscle strength and function in movements such as opening a jar, picking up coins or grasping or turning a key.

Interim data from the first cohort in its Phase II PATHWAY study in SCI showed improvement in strength and motor function at three months following transplant of its HuCNS-SC cells. Six patients with the most severe spinal cord injuries – complete loss of motor control below the level of injury – were injected between 10 and 23 months post injury, which is a timeframe you would not expect to see spontaneous recovery. In four of the six patients, motor improvement was detected from pre-treatment baseline as measured by the ISNCSCI (International Standards for Neurological Classification of Spinal Cord Injury) (three upgraded one level and one upgraded two levels) and GRASSP (Graded Assessment of Strength and Prehension).¹ Additionally, four of the six patients reported an overall improvement in condition based on the more subjective PGIC (Patient Global Impression of Change) assessment. Furthermore, improvements were seen in muscle strength in five of the six patients while four of these five improved on functional tasks measuring dexterity and fine motor skills. Importantly, the treatment was found to be safe with no adverse events associated with the stem cells.

¹ ISNCSCI assesses neurological level of injury by measuring the strength of five key muscle groups in each upper extremity. GRASSP assesses function (dexterity and fine motor skills) by measuring the strength of 10 key muscle groups in each upper extremity.

Exhibit 1: PATHWAY cohort 1 summary of six-month data

Subject	ISNCSCI Change in score from pre-transplant to 6 m		GRASSP Change in score from pre-transplant to 6 m		
	Upper Extremity Motor Score (Strength)	Level of cord injury (Unilateral Strength)	Upper Extremity Motor Score (Strength)	Prehension (Function)	
				Performance	Ability
A	↓	Stable	↑	↑	↑
B	Stable	↑	↑	↓	↓
C	↑	↑	↑	↑	↑
D	Stable	↑	↑	↑	↑
E	↑	↑	↑	↑	↑
F	↑	Stable	↓	↓	↓

Source: StemCells Cohort 1 interim review

Study is underway in the second cohort of 40 patients in the PATHWAY study, a randomized, controlled and single-arm of the trial. A third and optional six-patient cohort in motor incomplete injury is also provisionally planned in up to six subjects.² The timeline for announced data is as follows:

- Q216: cohort 1 12-month update
- H216: interim analysis cohort 2
- 2017: final pathway data

New leadership as COO Ian Massey takes over as CEO

Dr Ian Massey has stepped in as StemCells' new chief executive effective 18 January 2016 as former and long-standing CEO of 14 years, Martin McGlynn, retired. Dr Massey worked at the publicly traded Finish biotech company, Biotie, as COO and president of US operations before joining StemCells as COO in March 2015. Dr Massey brings more than 30 years of experience in the pharmaceuticals industry to his role as CEO. He held various senior executive research and development positions at Syntax and Roche before co-founding of Synosia, a licensor of drug candidates, which was eventually acquired by Biotie. Martin McGlynn will continue to serve as consultant for the company over the next year enabling a smooth handover of the leadership role.

Valuation adjusted for realignment of the company

Our valuation of StemCells moves to \$84m (\$0.77) from \$198m (\$1.82 per share) on the back of the amendments made to our models primarily on the company's recently announced realignment.

- Our rNPV in AMD moves to \$38m from \$160m as we push our forecasts back by two years to a 2023 launch, decrease our probability of success to 10% from 25% on increased uncertainty following the suspension of the program, and bring our royalty rate to 15% from 20% given the possibility of a partner now stepping in at an earlier stage of development.
- Conversely, given StemCells' intensified focus on its HuCNS in SCI and the positive interim results of the PATHWAY study, we increase our rNPV for the program to \$36m from \$11m, increasing our probability of success to 40% from 20% on the encouraging Phase II data. We

² Complete SCIs result in complete loss of motor control loss of function below the point of injury while incomplete SCIs refer to those with some feeling or movement below the point of injury.

also increase our royalty rate to 30% from 20% on StemCells' intention to move the program internally into pivotal Phase III and in the absence of related assumptions on one-off payments as part of deal terms.

We also roll our valuation forward by two quarters, continuing to use the Edison standard discount rate of 12.5%. We do not include potential share dilution from current out-of-the-money warrants and restricted stock.

Exhibit 2: StemCells valuation

Product	Status	Launch	NPV (\$m)	Peak sales (\$m)	Probability of success	Royalty rate	rNPV (\$m)	rNPV/share (\$)	Key assumptions
HuCNS-SC in SCI	Phase II	2021	127	333	40%	30%	36	0.33	US - SCI annual incidence: 12,500; 25% peak penetration (2026); \$50,000/dose. EU - SCI annual incidence: 10,500; 30% peak penetration (2026); \$40,000/dose.
HuCNS-SC in AMD	Phase II	2023	381	2,138	10%	15%	38	0.35	US - GA annual incidence: 310,000; 20% severe vision loss; 25% peak penetration (2026); 1.5 eyes treated; \$40,000/dose. EU - GA annual incidence: 680,000; 25% severe vision loss; 20% peak penetration (2026); 1.5 eyes treated; \$32,000/dose.
Portfolio total			508				74	0.68	
Net cash (end Q415 estimate)							10.4	0.10	
Equity valuation							84.1	0.77	

Source: Edison Investment Research

Financials

StemCells reported total revenue of \$37k in Q315 versus the \$82k reported in Q314 with sales primarily royalties on various licensing agreements. Stripping out certain non-cash charges (including significant swings related to the revaluing of warrants and depreciation), StemCells reported a non-GAAP net loss of \$8.4m as compared with \$6.0m in Q314 with the variance mainly related to increasing costs in Q3 associated with the progression of lead compounds into Phase II development in key indications (AMD and SCI) as well as stepped up costs for quality control, manufacturing and process development in support of the overall R&D effort. StemCells reported R&D of \$7.7m in Q315 (\$4.4m in Q314) and SG&A of \$2.3m (\$2.1m in Q314). We move our full year estimates in 2015 to a loss per share of \$0.39 from a loss per share of \$0.35 mainly due to higher expected cash operating expenses following that reported in Q315. In 2016 our forecasts move to a loss per share of \$0.25 from a loss per share of \$0.33, now including \$10m in savings on cost cutting, as guided by management, and partly offset by the \$400k in restructuring costs to be incurred in Q116.

Based on our estimated cash holdings \$11.9m at year end December 2015, StemCells will require additional financing in the early part of 2016 on our estimates and we therefore include an illustrative \$30m bank debt in our forecasts for 2016.

Exhibit 3: Financial summary

	\$'000s	2012	2013	2014	2015e	2016e
Year end 31 December		US GAAP				
PROFIT & LOSS						
Revenue		1,368	1,203	1,012	126	151
Cost of Sales		(263)	(317)	0	0	0
Gross Profit		1,105	887	1,012	126	151
Research and development		(15,847)	(20,534)	(21,503)	(27,951)	(20,963)
General & administrative		(7,447)	(8,897)	(10,420)	(9,258)	(5,833)
EBITDA		(23,181)	(29,602)	(32,218)	(38,228)	(27,944)
Operating Profit (before GW and except.)		(22,189)	(28,544)	(30,910)	(37,083)	(26,644)
Intangible Amortisation		0	0	0	0	0
Exceptionals/Other		(356)	(62)	0	0	0
Operating Profit		(22,546)	(28,605)	(30,910)	(37,083)	(26,644)
Net Interest		(35)	(1,155)	(1,287)	(492)	(23)
Other (includes change in fair value of warrants)		(5,911)	3,322	(544)	1,199	(400)
Profit Before Tax (norm)		(22,224)	(29,699)	(32,197)	(37,574)	(26,667)
Profit Before Tax (FRS 3)		(28,491)	(26,439)	(32,741)	(36,375)	(27,067)
Tax		0	0	0	0	0
Deferred tax		0	0	0	0	0
Profit After Tax (norm)		(22,224)	(29,699)	(32,197)	(37,574)	(26,667)
Profit After Tax (FRS 3)		(28,491)	(26,439)	(32,741)	(36,375)	(27,067)
Average Number of Shares Outstanding (m)		28.8	43.4	61.6	95.4	108.7
EPS - normalised (c)		(77.0)	(68.2)	(56.3)	(39.2)	(24.5)
EPS - FRS 3 (c)		(77.0)	(68.2)	(56.3)	(39.2)	(24.5)
Dividend per share (c)		0.0	0.0	0.0	0.0	0.0
BALANCE SHEET						
Fixed Assets		6,129	9,717	5,919	6,104	6,142
Intangible Assets		3,806	3,975	357	294	294
Tangible Assets		1,375	5,305	5,187	5,436	5,474
Other		947	437	375	374	374
Current Assets		24,041	31,840	26,508	12,955	19,176
Stocks		0	0	0	0	0
Debtors		110	109	159	3	3
Cash		22,372	30,585	24,988	11,868	18,089
Other		1,559	1,146	1,361	1,085	1,085
Current Liabilities		(5,097)	(9,132)	(11,498)	(8,635)	(7,182)
Creditors		(4,891)	(5,343)	(6,811)	(7,182)	(7,182)
Short term borrowings		(206)	(3,789)	(4,686)	(1,453)	0
Long Term Liabilities		(11,089)	(17,471)	(15,059)	(11,637)	(41,637)
Long term borrowings		(125)	(9,245)	(10,324)	(8,917)	(38,917)
Other long term liabilities		(10,964)	(8,226)	(4,734)	(2,720)	(2,720)
Net Assets		13,985	14,954	5,871	(1,213)	(23,501)
CASH FLOW						
Operating Cash Flow		(19,819)	(22,895)	(27,352)	(31,767)	(20,984)
Net Interest		(50)	(427)	0	0	(23)
Tax		0	0	0	0	0
Capex		(73)	(4,706)	(426)	(1,305)	(1,338)
Acquisitions/disposals		0	0	0	169	0
Financing		25,949	23,683	20,425	24,943	0
Dividends		0	0	0	0	0
Other		0	0	0	0	0
Net Cash Flow		6,006	(4,346)	(7,353)	(7,960)	(22,345)
Opening net debt/(cash)		(16,069)	(22,041)	(17,551)	(9,977)	(1,497)
HP finance leases initiated		0	0	0	0	0
Exchange rate movements		16	2	16	0	0
Other		(51)	(146)	(238)	(519)	19
Closing net debt/(cash)		(22,041)	(17,551)	(9,977)	(1,497)	20,828

Source: Company accounts, Edison Investment Research

Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER

Copyright 2016 Edison Investment Research Limited. All rights reserved. This report has been commissioned by StemCells and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited ("FTSE") © FTSE 2016. "FTSE®" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE's express written consent.